UAE-based Julphar announces entry into oncology market

Julphar will be partnering with BIOCAD and Health Authorities to register three leading specialised products to the UAE

  
A radiologist examines the brain X-rays of a patient who underwent a cancer prevention medical check-up at the North Bengal Oncology Center, a cancer hospital, on the outskirts of the eastern Indian city of Siliguri February 25, 2009. REUTERS/Rupak De Chowdhuri

A radiologist examines the brain X-rays of a patient who underwent a cancer prevention medical check-up at the North Bengal Oncology Center, a cancer hospital, on the outskirts of the eastern Indian city of Siliguri February 25, 2009. REUTERS/Rupak De Chowdhuri

REUTERS/Rupak De Chowdhuri

RAS AL KHAIMAH - Julphar has announced its entry into the oncology market through a licence-and-supply agreement with Russia’s leading biotechnology company, BIOCAD.

Julphar will be partnering with BIOCAD and Health Authorities to register three leading specialised products to the UAE, which are used to treat breast cancer, B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, colon cancer, lung cancer and glioblastoma.

Commenting on the announcement, Jerome Carle, General Manager of Julphar, said, "We are delighted to be partnering with BIOCAD in the UAE market as they have a proven track record and they support our core values. Entering the oncology market is a huge step forward for Julphar." "It will enable us to continue to focus on delivering healthcare solutions that make a real difference to people’s lives," he added.

Cancer is one of the biggest health burdens in the UAE. According to a report issued last month by the International Agency for Research on Cancer, IARC, of the World Health Organisation, WHO, breast cancer accounted for more than 20 percent of the total 4,707 new cancer cases that were found in the UAE in 2018.

"Cancer can be a very costly illness, placing a considerable financial burden on families," Carle said, adding that the launch of these products in the local market, "we would like to ensure that as many people as possible have access to life-saving medicines," he added.

Dmitry Morozov, CEO of BIOCAD, said, "Access to international markets is the number one priority of our company. That is why we consider our cooperation with one of the largest pharmaceutical companies in the Middle East a turning point in our international business development not only in the United Arab Emirates but also the Middle East and North Africa region, MENA, in general.

"Moreover, medicines produced by BIOCAD are competitive in their effectiveness as well as the price. Therefore, the presence of innovative Russian drugs in the UAE will help make important biological therapies widely accessible to patients. We are glad our products will increase access to treatment of the most severe types of cancer for more patients in the UAE than before," he concluded.

© Copyright Emirates News Agency (WAM) 2018.

More From Health